TRACON Pharmaceuticals (TCON)
(Delayed Data from NSDQ)
$1.81 USD
+0.02 (1.12%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.80 -0.01 (-0.55%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Cash flow Statements
Fiscal Year End for TRACON Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -3.59 | -29.14 | -28.67 | -16.78 | -22.67 |
Depreciation/Amortization & Depletion | 7.36 | 0.51 | -0.04 | 0.03 | 0.05 |
Net Change from Assets/Liabilities | -2.15 | -0.24 | 4.55 | -1.58 | -2.88 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 2.06 | 2.63 | 1.59 | 1.28 | 1.86 |
Net Cash From Operating Activities | 3.68 | -26.24 | -22.57 | -17.04 | -23.65 |
Property & Equipment | 0.00 | -0.02 | -0.05 | -0.01 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 4.00 | -4.00 | 14.02 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 0.00 | -0.02 | 3.95 | -4.00 | 14.02 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 7.96 | 7.97 | 13.36 | 38.16 | 2.33 |
Issuance (Repayment) of Debt | -20.50 | 11.71 | -2.80 | -1.40 | -1.40 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | -0.02 |
Net Cash from Financing Activities | -12.54 | 19.68 | 10.56 | 36.76 | 0.91 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -8.86 | -6.57 | -8.06 | 15.72 | -8.72 |
Cash at Beginning of Period | 17.50 | 24.07 | 32.13 | 16.41 | 25.14 |
Cash at End of Period | 8.64 | 17.50 | 24.07 | 32.13 | 16.41 |
Diluted Net EPS | -2.20 | -27.80 | -33.20 | -37.40 | -149.40 |
Fiscal Year End for TRACON Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -3.59 | -4.03 | -14.79 | -8.50 |
Depreciation/Amortization & Depletion | NA | 7.36 | 7.35 | 6.68 | 1.13 |
Net Change from Assets/Liabilities | NA | -2.15 | -0.69 | -3.81 | 1.80 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 2.06 | 1.57 | 1.07 | 0.57 |
Net Cash From Operating Activities | NA | 3.68 | 4.20 | -10.85 | -5.00 |
Property & Equipment | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 7.96 | 6.64 | 5.23 | 4.18 |
Issuance (Repayment) of Debt | NA | -20.50 | -20.50 | -10.00 | -10.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | -12.54 | -13.86 | -4.77 | -5.82 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -8.86 | -9.67 | -15.63 | -10.82 |
Cash at Beginning of Period | NA | 17.50 | 17.50 | 17.50 | 17.50 |
Cash at End of Period | NA | 8.64 | 7.84 | 1.87 | 6.68 |
Diluted Net EPS | NA | 3.20 | 5.80 | -4.00 | -7.20 |